Our Lead Program Targets Human TAS2R1

Amaro’s lead program is an oral small-molecule agonist of the human TAS2R1 receptor — a first-in-class approach integrating metabolic regulation and cellular senescence suppression.
Preclinical evidence shows TAS2R1 activation (and its mouse homolog Tas2r108) delivers a unique dual mechanism:

1. Metabolic Modulation via the Gut–Endocrine Axis

   1. Remodels enteroendocrine signaling, boosting GLP-1 and PYY

   2. Drives weight loss through decreased intake, reduced absorption, and increased expenditure

   3. Improves glucose tolerance, lipid profiles, and reduces hepatic steatosis without altering food intake or activity

2. Senomorphic Effects in Aging Tissues

   1. Reduces senescence markers (p21^Cip1, p16^INK4a) and SASP factors (TNFα, IL-6, IL-1β, MMP-3)

   2. Effects are TAS2R-mediated and occur alongside elevated GLP-1

Therapeutic Potential — Addressing metabolic dysfunction and inflammaging in one intervention with potential indications in obesity, type 2 diabetes, MASH, and other age-linked inflammatory conditions.
Combination Opportunity — Pairing with DPP-IV inhibitors amplifies GLP-1 secretion and further improves glucose control.
Amaro is advancing through chronic treatment studies and lead optimization to deliver a first-in-class therapy that restores metabolic balance, suppresses aging biology, and extends health span.